11/13
09:01 am
imrx
Immuneering (NASDAQ:IMRX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Medium
Report
Immuneering (NASDAQ:IMRX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
11/13
08:48 am
imrx
Rating for IMRX
Medium
Report
Rating for IMRX